Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma

NCT00928902 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT00928902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00928902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma
Lead sponsor
University of Virginia
Phase
Phase 2
Overall status
Completed
Start date
November 30, 1999
Completion date
March 31, 2005
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma